Consultant and Associate Professor Sean Wasserman at the Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital and University of Cape Town, appointed as Honorary Professor at the MRC Center for Medical Mycology at The Univeristy of Exeter.
Sean completed his MBChB and PhD at the University of Cape Town and obtained specialist qualifications in Internal Medicine and Infectious Diseases at the Colleges of Medicine of South Africa. He is a Consultant and Associate Professor in the Division of Infectious Diseases and HIV Medicine at Groote Schuur Hospital and UCT. He is Co-Lead of the Clinical Research Platform at the Wellcome Centre for Infectious Diseases Research in Africa, and Associate Member of the Institute for Infectious Disease and Molecular Medicine at UCT, where his main research area is treatment optimisation for tuberculosis and HIV-associated opportunistic infection. Sean is a pharmacologist on the ACTG Tuberculosis Transformative Science Group and a member of the NIH-CDC-HIVMA/IDSA Guidelines Committee for Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.
Current major trials include PRESCIENT, a multi-center Phase 2c trial of an ultra-short regimen for drug- susceptible pulmonary TB (NCT05556746); REVIVE, a multi-country Phase 3 trial of azithromycin prophylaxis for advanced HIV (NCT05580666); and an ACTG study evaluating the use of double dose dolutegravir with rifapentine-based therapy for HIV-associated TB (NCT05630872). Sean is an investigator on the IMPRINT Fungal HIV Global Health Research Group where he leads a cohort study on pneumocystis pneumonia. He also leads a cohort study investigating predictors of treatment outcome for drug-resistant TB in the Eastern Cape Province of South Africa.
Sean was profiled by the Lancet journal as a ‘rising star in TB-HIV research and medicine’ and has received awards from the International Society for Infectious Diseases, the InterAcademy Partnership, and the International Union against Tuberculosis and Lung Disease. Clinical interests include antimicrobial stewardship and infections in high-risk haematology patients.
Website links: